Keros Therapeutics (NASDAQ:KROS) Raised to “Hold” at Wall Street Zen

Keros Therapeutics (NASDAQ:KROS) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday, Wall Street Zen reports.

Several other research analysts also recently issued reports on the stock. Leerink Partners dropped their price objective on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a report on Tuesday, August 4th. Wells Fargo & Company reduced their target price on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research note on Tuesday, August 4th. Zacks Research raised Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Keros Therapeutics in a research report on Wednesday, August 12th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $21.40.

Keros Therapeutics Stock Performance

Shares of Keros Therapeutics stock opened at $9.33 on Monday. The company’s fifty day simple moving average is $11.11 and its 200-day simple moving average is $11.82. Keros Therapeutics has a 1 year low of $8.98 and a 1 year high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Thursday, November 5th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.96) by $1.66. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.85%. The business had revenue of $40.01 million for the quarter, compared to analyst estimates of $14.76 million. Equities analysts forecast that Keros Therapeutics will post -4.45 earnings per share for the current year.

Keros Therapeutics declared that its board has approved a share buyback plan on Wednesday, September 9th that permits the company to buy back $5 million in shares. This repurchase authorization permits the company to reacquire up to 2.3% of its shares through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In other Keros Therapeutics news, insider Lorena Raquel Lerner sold 3,568 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total transaction of $36,714.72. Following the sale, the insider directly owned 27,559 shares of the company’s stock, valued at approximately $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 5,343 shares of company stock worth $54,985 over the last quarter. 12.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Man Group plc acquired a new stake in Keros Therapeutics during the 2nd quarter valued at $1,664,000. Nantahala Capital Management LLC bought a new position in Keros Therapeutics in the 2nd quarter valued at $15,091,483. Empowered Funds LLC bought a new position in Keros Therapeutics in the 2nd quarter valued at $1,521,000. ADAR1 Capital Management LLC acquired a new position in Keros Therapeutics in the second quarter worth $2,641,000. Finally, Dimensional Fund Advisors LP boosted its stake in Keros Therapeutics by 453.9% in the first quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company’s stock worth $3,547,000 after purchasing an additional 263,347 shares in the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

More Keros Therapeutics News

Here are the key news stories impacting Keros Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $20 price target, while raising its estimates for FY2026 and FY2027 earnings per share (to losses of $3.33 and $5.25, respectively, from larger projected losses). Those improved forecasts could help investor sentiment. MarketBeat analyst estimates
• Positive Sentiment: A Zacks article said KROS had fallen 21% over four weeks and was technically oversold. It pointed to analyst earnings-estimate revisions as a possible catalyst for a rebound, though this is a technical outlook rather than a change in company fundamentals. Zacks article on KROS turnaround potential
• Neutral Sentiment: Wall Street Zen upgraded Keros to Hold, signaling a less negative view but not a bullish recommendation. Article on Wall Street Zen rating
• Neutral Sentiment: A short-interest report listed zero shares sold short as of November 10, despite describing a large increase. The figure therefore offers no clear indication of short-selling pressure and may warrant verification.
• Negative Sentiment: HC Wainwright lowered its FY2028–FY2030 earnings estimates, and its quarterly and annual forecasts still project substantial losses. The longer-term cuts temper the positive revisions for FY2026 and FY2027. MarketBeat analyst estimates

About Keros Therapeutics

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-?) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function. Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.